RNA Therapeutics 2016 to Spotlight on Immunotherapy and Cancer Therapeutics

SMi's 7th annual conference on RNA Therapeutics returns to London next February and will feature Five Spotlight Presentations on Immunotherapy and Cancer Therapeutics.

London, United Kingdom, December 12, 2015 --(PR.com)-- Due to significant investment and promising results in early phase clinical trials for chronic and rare diseases, recent reports have predicted the DNA and RNA therapeutics market to reach $1.2 billion by 2020. Of the 700 DNA and RNA therapeutics that are in the drug development pipeline, nearly 35% are targeting oncology.*

Following on from this, SMi’s 7th annual show on RNA Therapeutics, will include 5 spotlight presentations addressing key developments in immunotherapy and cancer therapeutics.

Featured presentations include:
1. A New Class of RNA Therapeutic: RIG-I
Christian Schetter, CEO & Managing Director, Rigontech GmbH
Presentation highlights will include insight into combinatorial approaches to boost immune and tumour response. Christian Schetter will introduce Rigontechs lead compound and discuss preclinical results as well as development opportunities.

2. RNA Vaccine Development and Optimising mRNA Therapeutics and Delivery
Mutafa Diken, Deputy Vice President, Immunotherapies and Pre-Clinical Research from BioNTech AG
Optimising mRNA for a specific immune response will be the focus of the address by one the fastest growing companies in Europe which will also include a review of clinical trials and preclinical data of immune responses.

3. Targeted Delivery of Antisense Oligonucleotides through Ligand-Conjugate Chemistry
Punit Seth, Executive Director, Isis Pharmaceuticals
This keynote presentation will discuss the challenges of targeted delivery beyond the liver and explore ligand receptor systems for successful delivery of oligoncleotide therapeutics.

4. Biotech 2.0 - Medical Revolution Through Natural mRNA - A focus on RNAActive®
Nigel Horscroft, Director Alliance Management, Curevac
There are 12 mRNA vaccines currently in development, seven of which are being developed by Curevac.* Hear more on pioneering mRNA technology platforms for vaccines and therapeutics in a compelling presentation where Curevac provide insight into RNAactive® and RNArt® with pre-clinical and clinical results.

5. Aptamers as a Delivery Vehicle Targeting Tumour Cells
David Bunka, Chief Technical Officer, Aptamer Group
The conference will end with guidance into the automated selection of cell targeted aptamers.

Further information in available online www.therapeutics-rna.com
RNA Therapeutics
15 – 16 February 2016
Holiday Inn Kensington Forum, London UK

Source: http://bit.ly/1RAivXk

About SMi:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
SMi Group
Teri Arri
+44 20 7827 6000